Neopharm Labs

What Neopharm Labs does

Neopharm Labs is a privately held, full-service GMP analytical testing laboratory headquartered in the Blainville/Montreal, Quebec region of Canada. Founded in 1990, the company provides analytical chemistry testing, microbiological testing, stability testing, impurities risk assessment, research and development services, and a Life Sciences division covering biopharmaceutical and gene/cell therapy analytics (ELISA, qPCR, LC/MS, peptide mapping, biomolecule characterization, cell banking). It also runs Health Canada-licensed cannabis testing and controlled substances testing. The portfolio rests on a combination of classical analytical instrumentation (LC/MS, SFC, preparative HPLC, Western blot, SDS-PAGE, sequencing) and proprietary methodologies such as the EPSA (Experimental Polar Surface Area) SFC assay and the Targeted Isolation impurity profiling technique.

The business serves five primary verticals: pharmaceutical manufacturers, cannabis producers, natural health product manufacturers, cosmetic manufacturers, and biopharmaceutical companies. Revenue is generated through project-based, quote-driven fees under master service agreements, with 30-day payment terms and 18% annualized interest on overdue balances. Sales are consultative and direct-to-enterprise, supported by content marketing (white papers, posters, webinars, a 5,000+ subscriber newsletter) and bilingual (English/French) web presence.

The company is differentiated by a rare combination of regulatory credentials — GMP, FDA inspection, Health Canada licensing, controlled drugs and substances license, Category A precursor license, and cannabis license — and by an integrated one-stop-shop model spanning the full product lifecycle from discovery through post-commercialization. Growth has been funded organically and through three disclosed acquisitions: Averica Discovery Services (United States, 2016), MS Pharma, and a 2024 cannabis testing acquisition. The company is founder- or management-owned, with no disclosed external private equity or venture capital backing.

Name

Neopharm Labs

Legal name

Neopharm Labs Inc.

Website

https://neopharmlabs.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Neopharm Labs is a privately held, GMP-certified Canadian analytical testing laboratory founded in 1990, serving pharmaceutical, biopharmaceutical, cannabis, natural health product, and cosmetic manufacturers with chemistry, microbiology, stability, impurities, and life sciences testing services from discovery through commercialization.

Ownership category

akta.pro rank

Product category

Pharmaceutical Analytical Testing Services

NAICS

Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

akta.pro secondary industries

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Pharmaceutical analytical testing
• GMP quality control
• Stability testing services
• Impurity risk assessment
• Cannabis analytical testing

Headquarters

HQ city

Blainville

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Analytical Testing Services: GMP quality control testing services for pharmaceutical, natural health product, and cosmetic manufacturers. Services include analytical chemistry testing, microbiology testing, stability testing, and R&D services. Revenue generated through project-based fees for testing services rendered across the product development lifecycle from research through commercialization.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Neopharm Labs is a full-service GMP-compliant analytical testing laboratory that performs chemistry, microbiology, stability, impurities, and biopharmaceutical testing on behalf of drug, biologic, cosmetic, natural health product, and cannabis manufacturers. Services span the full product lifecycle from R&D and clinical trials through commercialization and are delivered from Health Canada-licensed, FDA-inspected facilities in Quebec, Canada (with U.S. reach via the Averica Discovery acquisition). The company also provides specialized offerings such as the proprietary EPSA assay, controlled substances testing, and cannabis analytical services.

Product overview

Neopharm Labs provides a comprehensive suite of GMP-compliant analytical testing services for the life sciences, pharmaceutical, and cannabis industries. The portfolio includes core testing services (Analytical Chemistry Testing, Microbiology Analytical Testing, Stability Testing, Cannabis Testing Services), R&D services (Research & Development Services, Impurities Risk Assessment), and Life Sciences services for biopharmaceuticals. Under the Life Sciences umbrella, they offer specialized sub-services including Cell Banking Services, ELISA Services, qPCR Services, LC/MS Services, Peptide Mapping, Biomolecule Characterization, and Gene and Cell Therapies Services. The Impurities Risk Assessment service encompasses Nitrosamines Testing, Extractables and Leachables Studies, Elemental Impurities, PFAS Testing, and Purification Solutions. R&D Services include Method Development and Validation in Chemistry and Microbiology, Cleaning Validation, Filter Validation, Chiral Method Development, and Experimental Polar Surface Area (EPSA). Stability Testing services cover Storage and Testing, Photostability Studies, In-use Studies, Thermo-Cycling, and Custom Stability Studies. The company operates as a one-stop-shop solution provider, serving clients from research through clinical trials to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Analytical Chemistry Testing GMP-compliant analytical chemistry testing services for pharmaceutical and life sciences products, supporting quality control, regulatory compliance, and product development. Targeted at pharmaceutical manufacturers and life sciences companies.
• Cannabis Testing Services Specialized analytical testing services for cannabis products covering potency, purity, contaminants, and quality assessment under Health Canada licensing. Targeted at licensed cannabis producers and processors.
• Microbiology Analytical Testing Microbiological testing services for pharmaceutical and life sciences products, including sterility testing, microbial identification, antibiotic assays, and endotoxin testing. Targeted at pharmaceutical manufacturers requiring GMP microbiology release and in-process testing.
• Stability Testing Comprehensive stability testing services including ICH storage, photostability studies, in-use studies, thermo-cycling for transportation validation, custom stability protocols, drug product stress testing, and controlled substances stability testing in Health Canada licensed vaults. Targeted at pharmaceutical manufacturers needing ICH-compliant stability data for regulatory submissions.
• Research & Development Services R&D analytical services for pharmaceutical and life sciences clients, including method development and validation in chemistry and microbiology, compatibility studies, cleaning validation, filter validation, chiral method development, and disinfectant efficacy studies. Targeted at R&D and analytical development teams in pharmaceutical and life sciences companies.
• Impurities Risk Assessment Comprehensive impurity profiling and characterization services following ICH Q3A/Q3B guidelines, including nitrosamines analysis, extractables and leachables studies, elemental impurities, PFAS testing, related substances and foreign impurities analysis, unknown impurity identification, and Targeted Isolation impurity profiling. Targeted at pharmaceutical manufacturers needing impurity risk assessment for regulatory submissions.
• Life Sciences Biopharmaceutical analytical services for biologics, vaccines, and gene and cell therapy developers, including cell banking, ELISA, qPCR, SDS-PAGE and Western Blotting, LC/MS, peptide mapping, biomolecule characterization, gene and cell therapy analytics, and clinical biomarker assays. Targeted at biopharmaceutical companies developing advanced biologics and cell/gene therapies.

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• Averica DiscoveryminorOthersStrategic acquisition that expanded Neopharm's reach and services into the United States market. Integrated into the company structure to better support pharmaceutical industry partners.
• MS PharmaminorOthersAcquisition that expanded the company's service portfolio and geographic reach, integrated into Neopharm's unified entity to better support industry partners.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Eurofins Scientific: Global leader in bioanalytical, pharmaceutical, and life sciences testing services. Direct competitor to Neopharm across GMP analytical chemistry, microbiology, stability, and impurities work, with a substantially larger network of accredited labs.
• SGS: Global testing, inspection, and certification company with a sizable Life Sciences division offering pharmaceutical and biopharmaceutical analytical testing. Overlaps directly with Neopharm's QC, stability, and impurities service portfolio.
• Intertek: Global TIC provider with a Life Sciences and pharmaceutical testing practice covering analytical chemistry, stability, and biopharma support. Competes for the same pharma and consumer health testing contracts as Neopharm.
• Charles River Laboratories: Major CRO with a Biopharma Services / CDMO analytical offering spanning release testing, stability, impurities, and biomolecule characterization. Highly relevant competitor for Neopharm's biopharmaceutical analytical work.

Regional players

• Altasciences: Canadian-headquartered CRO offering preclinical, clinical, and bioanalytical services. Comparable as a fellow mid-size Canadian life sciences services provider, though with a different mix leaning more toward clinical bioanalysis.
• Nucro-Technics: Canadian pharmaceutical contract laboratory offering preclinical, analytical, bioanalytical, and toxicology services. A close regional peer to Neopharm with overlapping GMP analytical and stability testing capabilities in the Canadian market.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with extensive analytical, bioanalytical, and biologics testing capabilities. A broad incumbent competitor for Neopharm's biopharma and cell/gene therapy analytical services.
• Thermo Fisher Scientific (Patheon / PPD): Through Patheon (CDMO) and PPD (CRO), Thermo Fisher offers an integrated pharma services platform that includes analytical testing, stability, and bioanalytical work overlapping with Neopharm's offering.
• Catalent: Global biopharma CDMO with analytical development, release testing, and stability services for small and large molecule programs. A broader incumbent providing overlapping analytical capabilities to pharma clients.

Emerging players

• Cerba Research: Specialized central and specialty laboratory serving clinical trials and biopharma with bioanalytical, biomarker, and flow cytometry services. Comparable to Neopharm's clinical biomarker and bioanalytical offerings, though focused on trial support.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neopharmlabs
• LinkedInlinkedin.com/company/neopharm-labs-inc-

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neopharm Labs